Search clinical trials for: MenbVac

Total 28 results

University Hospital, Rouen
Institut Pasteur; Direction Générale de la Santé, France; Dieppe

Completed

Evaluation of Immune Response Against the Strain of Neisseria Meningitidis B: 14, P1-7, 16 Patients Vaccinated With MenBVac® (Extension MenbVac) (Exten MenbVac)

Vaccination With MenbVac

France
University Hospital, Rouen
Institut Pasteur; Direction Générale de la Santé, France

Completed

Evaluation of Immune Response Against the Strain of Neisseria Meningitidis B: 14, P1-7, 16 in Patients Having to be Vaccinated MenBVac® (Extension EFFIVAC) (Exten Effivac)

Neisseria Meningitidis

France
Public Health England

Completed

Immunogenicity and Reactogenicity of a Meningococcal B Outer Membrane Vesicle Vaccine Given in a 0,6,12 Month Schedule to Health UK Adults

Neisseria Meningitidis
Biofabri, S.L
University of Stellenbosch; University of Cape Town; TuBerculosis Vaccine Initiative and other collaborators

Recruiting

Efficacy, Safety and Immunogenicity Evaluation of MTBVAC in Newborns in Sub-Saharan Africa (MTBVACN3)

Tuberculosis

South Africa
Duke University

Recruiting

A Feasibility Study Utilizing Immune Recall to Increase Response to Checkpoint Therapy (TdVax)

Melanoma

United States
Biofabri, S.L
South African Tuberculosis Vaccine Initiative; TuBerculosis Vaccine Initiative and other collaborators

Completed

Dose-escalation Safety and Immunogenicity Study to Compare MTBVAC to BCG in Newborns With a Safety Arm in Adults (MTBVAC-Ph1b)

Tuberculosis

South Africa
Biofabri, S.L
South African Tuberculosis Vaccine Initiative; TuBerculosis Vaccine Initiative and other collaborators

Completed

Dose-Defining Safety and Immunogenicity Study of MTBVAC in South African Neonates (MTBVAC-03)

Tuberculosis

South Africa
HIV Vaccine Trials Network
National Institute of Allergy and Infectious Diseases (NIAID); Biofabri, S.L

Recruiting

Evaluating the Safety and Immunogenicity of MTBVAC in Adolescents and Adults Living With and Without HIV in South Africa (HVTN605A5421)

Tuberculosis | HIV I Infection

South Africa
International AIDS Vaccine Initiative
Biofabri, S.L; South African Tuberculosis Vaccine Initiative; Universidad de...

Completed

MTBVAC Study in Adults With and Without Latent Tuberculosis Infection in South Africa (A-050)

Tuberculosis

South Africa
GlaxoSmithKline

Completed

Assess the Immune Response Following Primary Vaccination With GSK Biologicals' Tritanrix™-HepB/Hib-MenAC vs Tritanrix™-HepB/Hiberix™ Given at 6,10 & 14 Wks of Age to Infants Who Received Hepatitis B Vaccine at Birth

Diphtheria; Haemophilus Influenzae Type b; Hepatitis B; Tetanus; Whole Cell Pertussis

South Africa
International AIDS Vaccine Initiative
Universidad de Zaragoza; Biofabri, SLU

Not yet recruiting

A Study to Evaluate the Efficacy, Safety and Immunogenicity of MTBVAC in IGRA Positive Adolescents and Adults Living in a TB Endemic Region.

Tuberculosis (TB)
GlaxoSmithKline

Completed

Immunogenicity & Safety Study of a Vaccine Against Meningitis in Infants (2,4,6 Months) After a Hepatitis B Birth Dose.

Hepatitis B | Tetanus | Diphtheria | Haemophilus Influenzae Type b | Whole Cell Pertussis

Thailand
GlaxoSmithKline

Completed

Assess if Immune Response of GSK Biologicals' Tritanrix™-HepB/Hib-MenAC Given Without or With Hepatitis B Vaccine at Birth is at Least as Good as Tritanrix™-HepB/Hiberix™ Without Hepatitis B Vaccine at Birth, When Given to Healthy Infants

Hepatitis B | Tetanus | Diphtheria | Haemophilus Influenzae Type b | Whole Cell Pertussis

Philippines
GlaxoSmithKline

Completed

A Study to Assess Antibody Persistence, Boostability & Safety in Previously Primed Subjects.

Hepatitis B | Tetanus | Diphtheria | Haemophilus Influenzae Type b | Whole Cell Pertussis

Philippines
GlaxoSmithKline

Completed

Assess Immune Response Following Primary Vaccination With Tritanrix™-HepB Vaccine Mixed With 3 Formulations of Hib-MenAC Vaccine to Infants

Hepatitis B | Pertussis | Tetanus | Diphtheria | Hib Diseases | Neisseria Meningitidis Serogroups A & C Diseases

Philippines
Sanofi Pasteur, a Sanofi Company

Completed

Safety and Immunogenicity in Adults of Revaccination With Adacel® Vaccine 10 Years After a Previous Dose

Pertussis | Whooping Cough | Tetanus | Diphtheria

United States, Canada
GlaxoSmithKline

Completed

Safety Study of Tritanrix-HepB/Hib-MenAC, Tritanrix-HepB/Hiberix, and Mencevax ACWY Vaccines in Children

Hepatitis B | Tetanus | Diphtheria | Haemophilus Influenzae Type b | Whole Cell Pertussis | Diphtheria-Tetanus-Pertussis-Hepatitis B-Haemophilus Influenzae Type b-Neisseria Meningitidis Vaccin

Thailand, Philippines
GlaxoSmithKline

Completed

Lot-to-lot Consistency of Tritanrix™-HepB/Hib-MenAC & Its Non-inferiority vs Tritanrix™-HepB/Hiberix™ in Infants

Hepatitis B | Tetanus | Diphtheria | Haemophilus Influenzae Type b | Whole Cell Pertussis

Thailand
Sanofi Pasteur, a Sanofi Company

Completed

Canadian Manufactured Tetanus and Diphtheria Toxoids Adsorbed (Td) Vaccine Compared With U.S. Manufactured Td

Tetanus | Diphtheria

United States
Zagazig University

Completed

Intralesional Versus Intramuscular Hepatitis B Vaccine Immunotherapy for Warts

Intralesional Versus Intramuscular Hepatitis B Vaccine for Multiple Common Warts

Egypt
Biofabri, S.L
Centre Hospitalier Universitaire Vaudois; TuBerculosis Vaccine Initiative; Universidad...

Completed

Dose-Escalation Study to Evaluate the Safety and Immunogenicity of MTBVAC Vaccine in Comparison With BCG Vaccine. (MTBVAC)

Healthy | Tuberculosis

Switzerland
Chiang Mai University
Faculty of Medicine, Chiang Mai University

Not yet recruiting

Immunogenicity and Safety of Inactivated and Live-attenuated HAV Vaccine Among Thai Healthy Children and Adolescents (HAV-RCT)

Hepatitis A | Vaccine-Preventable Diseases | Hep A | HAV
GlaxoSmithKline

Completed

Response to GSK Biologicals' Tritanrix-HepB/Hib-MenAC Vacc (4th Dose) at 15-24m & Mencevax ACWY at 24-30m

Hepatitis B | Tetanus | Diphtheria | Haemophilus Influenzae Type b | Whole Cell Pertussis | Diphtheria-Tetanus-Pertussis-Hepatitis B-Haemophilus Influenzae Type b-Neisseria Meningitidis Vaccin

Thailand
Katy Peters, MD, PhD

Completed

IDH1 Peptide Vaccine for Recurrent Grade II Glioma (RESIST)

Brain Cancer | Brain Tumor | Brain Neoplasm, Primary | Brain Neoplasms, Recurrent | Cancer of the Brain

United States
GlaxoSmithKline

Completed

Safety Study of a Vaccine Against Meningitis in Infants ( 2,4 & 6 Months Age) After a Birth Dose of Hepatitis B.

Hepatitis B | Tetanus | Diphtheria | Haemophilus Influenzae Type b | Whole Cell Pertussis

Philippines
GlaxoSmithKline

Completed

Safety Study of a Vaccine Against Meningitis in Infants (2,4 & 6 Months Age) After a Birth Dose of Hepatitis B.

Hepatitis B | Tetanus | Diphtheria | Haemophilus Influenzae Type b | Whole Cell Pertussis

Thailand
Beijing Zhifei Lvzhu Biopharmaceutical Co., Ltd
Air Force Military Medical University, China; Guizhou Center for Disease Control... and other collaborators

Unknown

Immunogenicity and Safety of Meningococcal Groups A and C and Haemophilus b Conjugate Vaccine in Infants 2 to 5 Months of Age

Meningitis | Meningococcal Infections | Meningococcal Meningitis

China
Biogen

Completed

Vaccination Response in Tecfidera-Treated Versus Interferon-Treated Participants With Relapsing Forms of Multiple Sclerosis.

Relapsing Forms of Multiple Sclerosis

United States

Search clinical trials for: MenbVac

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in South Korea

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations